Shares of Intercept Pharmaceuticals Inc ICPT were trading higher by more than 6 percent ahead of Tuesday's market open as investors found the U.S. Food and Drug Administration's (FDA) latest briefing documents to be encouraging.
The FDA has a scheduled advisory committee meeting on Thursday and will discuss the new drug application 20799, obeticholic acid oral tablets, submitted by Intercept Pharmaceuticals for the treatment of primary biliary cirrhosis in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA.
The Street's biotech columnist Adam Feuerstein Tweeted that he doesn't "see any nasty surprises in the FDA's summary of the OCA data." He added in a follow up Tweet that the stock's "current valuation already exceeds potential sales of OCA in PBC, so label restriction to mild patients doesn't really batter."
Market News and Data brought to you by Benzinga APIs$ICPT — I don't see any nasty surprises in the FDA's summary of the OCA data. Questions/debate on patient selection, endpt appropriateness.
— Adam Feuerstein (@adamfeuerstein) April 5, 2016
$ICPT current valuation already exceeds potential sales of OCA in PBC, so label restriction to mild patients doesn't really matter.
— Adam Feuerstein (@adamfeuerstein) April 5, 2016
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in